| abstract |
The novel heterocyclic compound of the present invention is a novel heterocyclic compound having the formula (I) n n n Y: n n n wherein R 1 is H or C 1-6 alkyl, R 2 is H, —CO—C(R 4 )═C(R 4 )—R 5 wherein R 4 is H or C 1-4 alkyl, and R 5 is C 4-8 alkyl, C 2-8 alkenyl and the like, and the like, Y is the following group wherein X is O or S, R 7 is the same as R 4 , R 8 is R 10 —C(R 9 )═C(R 9 )— wherein R 9 is the same as R 4 , R 10 is C 3-6 alkyl and the like, and the like, R 14 is the same as R 4 , and R 15 is aryl and the like, Y—(CH 2 )n-O— is bonded to the 6- or 7-position of the tetrahydroisoquinoline skeleton, and n is an integer of 1 to 4, or a pharmaceutically acceptable salt thereof. The compound (I) of the present invention is useful as a hypoglycemic agent, a hypolipidemic agent, an insulin resistance improver, a therapeutic agent of diabetes, a therapeutic agent of diabetic complications, a glucose tolerance improver, an anti-arteriosclerosis agent, an anti-obesity agent, an antiinflammatory agent, an agent for the prophylaxis or treatment of PPAR-mediated diseases or an agent for the prophylaxis or treatment of syndrome X. |